A dose finding study of fluvastatin for in vivo demonstration of inhibiting hepatitis C replication in patients infected with chronic hepatitis C with special attention to the African-American population.

Trial Profile

A dose finding study of fluvastatin for in vivo demonstration of inhibiting hepatitis C replication in patients infected with chronic hepatitis C with special attention to the African-American population.

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Jul 2012

At a glance

  • Drugs Fluvastatin (Primary)
  • Indications Hepatitis C
  • Focus Pharmacodynamics
  • Most Recent Events

    • 26 Jul 2012 Official title ammended and additional lead trial centre added as reported by ClinicalTrials.gov record.
    • 26 Jul 2012 Actual end date (September 2007) added as reported by ClinicalTrials.gov.
    • 06 Apr 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top